Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mingmu Xunxi Decoction is a traditional Chinese medicine (TCM) herbal formula used primarily for the treatment of ocular surface diseases, particularly Meibomian gland dysfunction and other chronic eye conditions. The formula is typically administered as a decoction for external use (eye washing or steaming). It is composed of multiple herbs selected to "brighten the eyes," nourish blood, clear obstructions, and restore function according to TCM theory. While specific ingredient lists may vary by practitioner or region, common components include Lycium barbarum (goji berry), Polygonatum species, Ophiopogon japonicus, Poria cocos, Glycyrrhiza uralensis (licorice), Eclipta prostrata, and Ligusticum striatum[1][2]. Mechanistically, studies suggest that similar formulas act by modulating oxidative stress pathways and cellular senescence in ocular tissues via inhibition of p38 MAPK signaling and downstream p53/p21 pathways[1]. Clinical trials have investigated its efficacy in improving symptoms related to Meibomian gland dysfunction[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mingmu Xunxi Decoction.